ReviewJournal of cellular physiology2014
Advances in androgen receptor targeted therapy for prostate cancer.
Review in Journal of cellular physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- An Estimate of the Incidence of Prostate Cancer in Africa: A Systematic Review and Meta-Analysis.PloS one · 2016Pooled it
- Comparative Effectiveness of Management Strategies for Stage IV Prostate Cancer: A Narrative Review.Cureus · 2025Review
- Article
- Phytochemical identification and in silico elucidation of interactions of bioactive compounds fromIn silico pharmacology · 2024Article
- Cancer-biomarkers associated with sex hormone receptors and recent therapeutic advancements: a comprehensive review.Medical oncology (Northwood, London, England) · 2023Review
- Prostate cancer treatment and the relationship of androgen deprivation therapy to cognitive function.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer.Cancer informatics · 2022Article
- Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening.Frontiers in oncology · 2022Review
- New benzothieno[2,3-Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Treatment and trials in non-metastatic castration-resistant prostate cancer.Nature reviews. Urology · 2021Review
- Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers.Biomolecules · 2021Review
- Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.Cellular and molecular life sciences : CMLS · 2020Article
- The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy.Biomedicines · 2020Review
- A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells.American journal of cancer research · 2020Article
- The Immunogenic Potential of Recurrent Cancer Drug Resistance Mutations: AnFrontiers in immunology · 2020Article
- Clinicopathological and prognostic significance of androgen receptor overexpression in colorectal cancer. Experience from Al-Madinah Al-Munawarah, Saudi Arabia.Saudi medical journal · 2019Article
- A Review of Curcumin and Its Derivatives as Anticancer Agents.International journal of molecular sciences · 2019Review
- Androgen receptor promotes oral squamous cell carcinoma cell migration by increasing EGFR phosphorylation.OncoTargets and therapy · 2019Article
- MicroRNA-218 inhibits the migration, epithelial-mesenchymal transition and cancer stem cell properties of prostate cancer cells.Oncology letters · 2018Article
- Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells.Medicina (Kaunas, Lithuania) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa) is the second leading cause of cancer death in men. Current research findings suggest that the androgen receptor (AR) and its signaling pathway contribute significantly to the progression of metastatic PCa. The AR is a ligand activated transcription factor, where androgens such as testosterone (T) and dihydroxytestosterone (DHT) act as the activating ligands. However in many metastatic PCa, the AR functions promiscuously and is constitutively active through multiple mechanisms. Inhibition of enzymes that take part in androgen synthesis or synthesizing antiandrogens that can inhibit the AR are two popular methods of impeding the androgen receptor signaling axis; however, the inhibition of androgen-independent activated AR function has not yet been fully exploited. This article focuses on the development of emerging novel agents that act at different steps along the androgen-AR signaling pathway to help improve the poor prognosis of PCa patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.